Related references
Note: Only part of the references are listed.Absence of functional EpoR expression in human tumor cell lines
Susan Swift et al.
BLOOD (2010)
Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells
Angus M. Sinclair et al.
BLOOD (2010)
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
J. Glaspy et al.
BRITISH JOURNAL OF CANCER (2010)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
Michael A. Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
Julia Bohlius et al.
LANCET (2009)
Tumor Progression Associated with Erythropoiesis-Stimulating Agents
Ashley M. Newland et al.
ANNALS OF PHARMACOTHERAPY (2008)
Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer
Gillian Thomas et al.
GYNECOLOGIC ONCOLOGY (2008)
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
Charles L. Bennett et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis
Tatsuma Okazaki et al.
NEOPLASIA (2008)
Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: A randomized trial of the radiation therapy oncology group (RTOG 99-03)
Mitchell Machtay et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation
S. M. Temkin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial
PM Wilkinson et al.
BRITISH JOURNAL OF CANCER (2006)
Erythropoietin or Darbepoetin for patients with cancer
J. Bohlius et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2006)
Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature
Susan D. Ross et al.
CLINICAL THERAPEUTICS (2006)
Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial
JH Savonije et al.
EUROPEAN JOURNAL OF CANCER (2005)
Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy
J Chang et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study
B Leyland-Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy:: randomised, double-blind, placebo-controlled trial
M Henke et al.
LANCET (2003)
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
J Crawford et al.
CANCER (2002)
Share Paper
